Vitamin B12 on GLP-1 therapy: who is at risk, the range, and why metformin is the real reason it is on the panel

Vitamin B12 is on a lot of GLP-1 lab panels and in none of the GLP-1 labels. Both facts are correct. The test is there because of the other things going on in the people being treated, and it is worth knowing which of those apply to you so you can tell whether it is worth repeating.

What the test measures

Serum B12 measures the vitamin circulating in blood, in picograms per millilitre. B12 is needed to make red blood cells and to maintain nerves; a deficiency causes a particular kind of anemia (large red cells, a high MCV on the CBC) and, if it goes on, numbness, tingling and balance problems. MedlinePlus gives a common range of 299 to 1054 pg/mL (219 to 773 pmol/L) and says values under 299 pg/mL are a possible sign of deficiency. It adds the important step: deficiency should be confirmed by checking methylmalonic acid (MMA), which rises when cells cannot get enough usable B12. Ranges vary between laboratories, and the low cut-off in particular differs.

Why it is on the panel

Metformin. Many people starting a GLP-1 for weight, and most with type 2 diabetes, are on metformin. Metformin reduces B12 absorption, and the ADA Standards of Care suggest periodic measurement of B12 in people taking it, especially those with anemia or peripheral neuropathy. This is the single most common reason a B12 appears on a GLP-1 baseline panel.

Acid reduction. B12 is released from food by stomach acid. The NIH Office of Dietary Supplements lists long-term use of proton pump inhibitors and H2 blockers as a risk factor for deficiency. Reflux and nausea are common on GLP-1 therapy, and acid reducers get added.

Diet. B12 comes only from animal foods and fortified products. Vegans and many vegetarians depend on supplements. Someone eating a fraction of their former volume, which is the point of the drug, may be eating a fraction of their former B12, particularly if meat is what they have gone off.

Bariatric surgery. Gastric bypass and sleeve procedures reduce B12 absorption for life. People who had surgery years ago and now start a GLP-1 sometimes have not had a B12 checked in a long while.

Age. Absorption falls with age; the NIH notes that adults over 50 may absorb less B12 from food.

Why it is not in the labels

The Wegovy, Ozempic, Zepbound and Mounjaro labels do not list B12 deficiency as an adverse reaction, do not list it under laboratory abnormalities, and do not ask for monitoring. The drugs slow gastric emptying, which affects how fast oral medicines are absorbed, but there is no label statement that they reduce B12 absorption. This site does not extend the label further than it goes.

How often

• On metformin: periodic, per the ADA; many prescribers make that yearly.
• Other risk factors (acid reducers, vegan or vegetarian diet, bariatric history, age over 50): at baseline, then as your prescriber advises, more often if symptoms appear.
• No risk factors: no label or guideline sets an interval. A baseline is reasonable if you expect a long period of very low intake; repeating a normal result in the absence of risk factors adds little.
• Symptoms: numbness, tingling, a sore tongue, unusual fatigue with a high MCV on a CBC. Check now.

Reading the result

A result just above the lower limit in someone with symptoms or a high MCV deserves the MMA confirmation. A result far above the upper limit usually means a recent supplement or injection and is not itself a problem. Because B12 is a water-soluble vitamin, there is no upper toxicity limit set by the NIH.

What to discuss with your prescriber

• Whether metformin, an acid reducer, your diet or past surgery puts you in a risk group.
• If you supplement already: whether the dose and form are still right when intake is very low.
• What a borderline result would trigger (MMA, a trial of supplementation, a CBC).

The Weight Loss on GLP-1s site covers protein and nutrient intake on therapy in detail. For a full baseline list, see the pre-therapy lab checklist.